JP2018515490A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515490A5
JP2018515490A5 JP2017557329A JP2017557329A JP2018515490A5 JP 2018515490 A5 JP2018515490 A5 JP 2018515490A5 JP 2017557329 A JP2017557329 A JP 2017557329A JP 2017557329 A JP2017557329 A JP 2017557329A JP 2018515490 A5 JP2018515490 A5 JP 2018515490A5
Authority
JP
Japan
Prior art keywords
composition
compound
carcinoma
tumor
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017557329A
Other languages
English (en)
Japanese (ja)
Other versions
JP6946194B2 (ja
JP2018515490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/031027 external-priority patent/WO2016179415A1/en
Publication of JP2018515490A publication Critical patent/JP2018515490A/ja
Publication of JP2018515490A5 publication Critical patent/JP2018515490A5/ja
Application granted granted Critical
Publication of JP6946194B2 publication Critical patent/JP6946194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017557329A 2015-05-06 2016-05-05 キナーゼを調節する化合物の固体形態 Active JP6946194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157902P 2015-05-06 2015-05-06
US62/157,902 2015-05-06
PCT/US2016/031027 WO2016179415A1 (en) 2015-05-06 2016-05-05 Solid forms of a compound modulating kinases

Publications (3)

Publication Number Publication Date
JP2018515490A JP2018515490A (ja) 2018-06-14
JP2018515490A5 true JP2018515490A5 (cg-RX-API-DMAC7.html) 2019-06-06
JP6946194B2 JP6946194B2 (ja) 2021-10-06

Family

ID=56008880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017557329A Active JP6946194B2 (ja) 2015-05-06 2016-05-05 キナーゼを調節する化合物の固体形態

Country Status (29)

Country Link
US (4) US9802932B2 (cg-RX-API-DMAC7.html)
EP (2) EP3757104A1 (cg-RX-API-DMAC7.html)
JP (1) JP6946194B2 (cg-RX-API-DMAC7.html)
KR (1) KR102630889B1 (cg-RX-API-DMAC7.html)
CN (1) CN107548394B (cg-RX-API-DMAC7.html)
AU (1) AU2016258027B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017023490B1 (cg-RX-API-DMAC7.html)
CA (1) CA2984910C (cg-RX-API-DMAC7.html)
CO (1) CO2017011534A2 (cg-RX-API-DMAC7.html)
CY (1) CY1123796T1 (cg-RX-API-DMAC7.html)
DK (1) DK3292123T3 (cg-RX-API-DMAC7.html)
ES (1) ES2820827T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201383T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050506T2 (cg-RX-API-DMAC7.html)
IL (1) IL255313A0 (cg-RX-API-DMAC7.html)
LT (1) LT3292123T (cg-RX-API-DMAC7.html)
MX (1) MX386963B (cg-RX-API-DMAC7.html)
MY (1) MY192352A (cg-RX-API-DMAC7.html)
NZ (1) NZ737616A (cg-RX-API-DMAC7.html)
PH (1) PH12017501995A1 (cg-RX-API-DMAC7.html)
PT (1) PT3292123T (cg-RX-API-DMAC7.html)
RS (1) RS60731B1 (cg-RX-API-DMAC7.html)
RU (1) RU2730506C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201912355TA (cg-RX-API-DMAC7.html)
SI (1) SI3292123T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000535T1 (cg-RX-API-DMAC7.html)
TW (1) TWI727949B (cg-RX-API-DMAC7.html)
WO (1) WO2016179415A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708007B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
LT2672967T (lt) 2011-02-07 2018-12-10 Plexxikon Inc. Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
MX2015002887A (es) 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2774178T3 (es) 2015-05-06 2020-07-17 Plexxikon Inc Síntesis de derivados de 1h-pirrolo[2,3-B] piridina que modulan cinasas
TWI727949B (zh) 2015-05-06 2021-05-21 美商普雷辛肯公司 調節蛋白質激酶之化合物的固態形式
ES2825202T3 (es) 2015-05-22 2021-05-14 Plexxikon Inc Síntesis de compuestos heterocíclicos
CN113893253A (zh) 2015-05-22 2022-01-07 普莱希科公司 用于治疗braf-v600相关的疾病的plx-8394或plx-7904
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN113754656A (zh) 2015-09-21 2021-12-07 普莱希科公司 杂环化合物及其应用
RU2018123825A (ru) 2015-12-07 2020-01-15 Плексксикон Инк. Соединения и способы для модуляции киназ, и показания для этого
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
WO2017215521A1 (zh) * 2016-06-17 2017-12-21 苏州科睿思制药有限公司 Plx3397的盐酸盐晶型及其制备方法和用途
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ido及tdo調節之化合物及方法以及其適應症
EP3558991A2 (en) 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
ES2896502T3 (es) 2017-03-20 2022-02-24 Plexxikon Inc Formas cristalinas de ácido 4-(1-(1,1-di(piridin-2-il) etil)-6-(3,5-dimetilisoxazol-4-il)-1H-pirrolo[3,2-b]piridin-3- il)benzoico que inhiben el bromodominio
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
AU2018307910B2 (en) * 2017-07-25 2024-07-25 Daiichi Sankyo Company, Limited Formulations of a compound modulating kinases
JP7675519B2 (ja) 2017-10-13 2025-05-13 オプナ バイオ ソシエテ アノニム キナーゼを調節するための化合物の固体形態
KR102849779B1 (ko) 2017-10-27 2025-08-25 플렉시콘 인코퍼레이티드 키나제를 조정하는 화합물의 제제
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
AU2020271836B2 (en) 2019-04-09 2025-11-13 Opna Bio SA Condensed azines for EP300 or CBP modulation and indications therefor
AU2021261383A1 (en) 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
US11739088B2 (en) 2020-04-29 2023-08-29 Plexxikon Inc. Synthesis of heterocyclic compounds
EP4178982A1 (en) 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
JP7472391B2 (ja) * 2020-07-22 2024-04-22 南京正大天晴制薬有限公司 ジヒドロピリド[2,3-d]ピリミジノン誘導体の塩及び結晶形
CA3192047A1 (en) 2020-08-21 2022-02-24 Plexxikon Inc. Combinational drug anticancer therapies
JP7628342B2 (ja) * 2020-09-25 2025-02-10 成都嘉葆薬銀医薬科技有限公司 1H-ピロロ[2,3-c]ピリジン系化合物及びその使用
US20220251218A1 (en) * 2021-02-10 2022-08-11 Gnt Biotech & Medicals Corporation Pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer
US20240189277A1 (en) * 2021-04-16 2024-06-13 The Johns Hopkins University Ophthalmic formulations for sustained neuroprotection
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
KR20130023381A (ko) 2003-07-17 2013-03-07 플렉시콘, 인코퍼레이티드 Ppar 활성 화합물
US7517970B2 (en) 2003-12-19 2009-04-14 Plexxikon, Inc. Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ret調節剤の開発のための化合物および方法
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン,インコーポレーテッド Pde4b阻害剤及びその使用
RU2389728C2 (ru) * 2004-07-27 2010-05-20 Сгкс Фармасьютиклз, Инк. Модуляторы киназы на основе производных пирролопиридина
CA2583428A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
CA2608733A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
CN102603581B (zh) 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
CN104530052A (zh) 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
RU2011141123A (ru) 2009-03-11 2013-04-20 Плексксикон, Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RAF-КИНАЗ
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
PH12012500900A1 (en) 2009-11-06 2012-11-12 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
RU2012125070A (ru) 2009-11-18 2013-12-27 Плексксикон, Инк. Соединения и способы модулирования киназы и показания к их применению
BR112012015745A2 (pt) 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US8642606B2 (en) 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
LT2672967T (lt) 2011-02-07 2018-12-10 Plexxikon Inc. Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
CN103917235A (zh) 2011-05-17 2014-07-09 普莱希科公司 激酶调节及其适应症
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
MX2015002887A (es) 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016044067A1 (en) 2014-09-15 2016-03-24 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2774178T3 (es) 2015-05-06 2020-07-17 Plexxikon Inc Síntesis de derivados de 1h-pirrolo[2,3-B] piridina que modulan cinasas
TWI727949B (zh) 2015-05-06 2021-05-21 美商普雷辛肯公司 調節蛋白質激酶之化合物的固態形式
ES2825202T3 (es) 2015-05-22 2021-05-14 Plexxikon Inc Síntesis de compuestos heterocíclicos
CN113893253A (zh) 2015-05-22 2022-01-07 普莱希科公司 用于治疗braf-v600相关的疾病的plx-8394或plx-7904
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN113754656A (zh) 2015-09-21 2021-12-07 普莱希科公司 杂环化合物及其应用
RU2018123825A (ru) 2015-12-07 2020-01-15 Плексксикон Инк. Соединения и способы для модуляции киназ, и показания для этого
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ido及tdo調節之化合物及方法以及其適應症
EP3558991A2 (en) 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
ES2896502T3 (es) 2017-03-20 2022-02-24 Plexxikon Inc Formas cristalinas de ácido 4-(1-(1,1-di(piridin-2-il) etil)-6-(3,5-dimetilisoxazol-4-il)-1H-pirrolo[3,2-b]piridin-3- il)benzoico que inhiben el bromodominio

Similar Documents

Publication Publication Date Title
JP2018515490A5 (cg-RX-API-DMAC7.html)
HRP20201383T1 (hr) Kruti oblici spoja za moduliranje kinaza
JP7189956B2 (ja) Sos1阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
JP6965360B2 (ja) o−アミノヘテロアリールアルキニル基含有化合物およびその製造方法と用途
AU2018267622B2 (en) Alkyne substituted quinazoline compound and methods of use
AU2015306561B2 (en) Indazole compounds as FGFR kinase inhibitor, preparation and use thereof
AU2015227454B2 (en) Functionalised and substituted indoles as anti-cancer agents
IL283184B2 (en) Crystal polymorph of (7s,13r)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10] benzoxatriazacyclotridecin–4(5h)–one for the treatment of cancer
WO2001083456A1 (en) Condensed heteroaryl derivatives
CN106749261A (zh) 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
WO2017101884A1 (zh) 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
JP2014524476A5 (cg-RX-API-DMAC7.html)
WO2016008010A1 (en) Functionalised and substituted carbazoles as anti-cancer agents
WO2004071507A1 (en) Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
KR20230163335A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
TWI755418B (zh) 聯芳組成物和調控激酶級聯之方法
CA2813063A1 (en) Antagonist for mutated androgen receptor
CN109476649B (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
TWI374880B (en) A pharmaceutically acceptable salt and solvate of n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methylmethanesulfonamide and uses thereof
JP7618575B2 (ja) N-(5-((4-エチルピペラジン-1-イル)メチル)ピリジン-2-イル)-5-フルオロ-4-(3-イソプロピル-2-メチル-2h-インダゾール-5-イル)ピリミジン-2-アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
CN110066236B (zh) 1h-吡咯衍生物、其制备方法、药物组合物及应用
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
JP2022537385A (ja) 大環状キナーゼ阻害剤の多形
AU2013252944B2 (en) Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
WO2014029250A1 (zh) 苯并吡啶氮杂卓类化合物及其应用